This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MarketVIEW: Japanese Encephalitis Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Japanese encephalitis vaccines

Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental "dead end" hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE. 

This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project. 


Contents – Summary presentation (MS PowerPoint based)ContentsAuthors noteExecutive summaryCommercial model: key outputsJE vaccine: available market (endemic/public) ($ 000s) – all children to 2030JE vaccine: available market (endemic/public) ($ 000s) – infants to 2030JE vaccine: available market (endemic/public) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: endemic segment volume analysis (mio doses/yr)JE vaccine: available market (endemic/private) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: market by vaccine type 2015JE vaccines: all market segments, revenues/yr (2015)JE: disease backgroundJE: transmission cycleJE: geographic distributionJE: epidemiologyJE: genotype distributionJE: country reporting/surveillanceJE: WHO reported cases 2006 - 2010JE: disease profile of main endemic countriesRisk of JE by country, region and seasonDALYs per 100,000 persons in JE endemic countriesJE: disease trends and dynamicsJE: factors contributing to increasing transmissionJE and travelersJE: control and preventionJE control: aligned with major stakeholder objectivesPATH JE project: strategic goalsJE vaccines: policy evolutionJE vaccines: immunological aspectsImpact of JE vaccinationJE vaccination and cost effectivenessCurrently licensed JE vaccines (endemic)Country status of JE control through immunizationCountry use of JE vaccine types: SEA regionCountry use of JE vaccine types: WPR regionIndia: cases and deaths 1993 – 2009India – JE priority districtsIndia – mass vaccination campaignsIndia – mass vaccination campaigns: progress to dateTransition to new JE vaccinesAvailability of new JE vaccinesJE vaccination: country future planning – SEA regionJE vaccination: country future planning – WPR regionCommercial model: detailed assumptions per WHO region/countryJE vaccine demand forecast: countries modelledJE vaccines: modelling strategyCommercial model assumptions – SEA regionCommercial model assumptions – WPR regionPricing case studies for endemic vaccinesJE vaccine prices used in modelSource materialJE vaccines (PATH): estimated implementation 2006 – 2015Timeline of JE in Thailand 1971 – 2006Japan: immunization schedule 2011 (< 20 yrs) Japan: JEV vaccinations given 1995 – 2009 (000s)Ensebakku subcutaneous JE vaccine: History of developmentIxiaro/JESPECT – distribution structureBibliographyAbout VacZine AnalyticsDisclaimerBack pagePAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based) – endemic markets (public/private)Title sheetCHARTS – VAL (private)CHARTS – VAL (pub)CHARTS – VOL (pub)GRAND VALUE SUMMARYValue by vaccine typeValue Summary (pub <1 yrs)>Value Summary (pub 1-15 yrs)Value Summary (priv 0 - 15 yrs)Global price summaryVolume Summary (pub <1 yrs)>Volume Summary (pub 1-15 yrs)Volume Summary (priv 0 - 15 yrs)Volume SummariesSEA regionBangladesh (pub) Bangladesh (priv) Bhutan (pub) Bhutan (priv) India (pub) India (priv) Indonesia (pub)

Indonesia (priv)

Korean DPR (pub)

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs